- 稀释计算器 | Tocris Bioscience
- Tocris代理_Tocris蚂蚁淘
- 人抗神经节苷脂抗体试剂盒上海报价
- Tocris bioscience 代理
- Tocris: R&D Systems
- DMPO_CAS号3317611_M6685说明书_AbMole中国
- Submit a Product Review | Tocris Bioscience
- TOCRIS GPCR ligands 神经传递素离子通道调控剂信号通路抑制剂...
- 进口试剂Tocris直采 TOCRIS 437210MG,Tocris/NVP CXCR2 20/5660...
- Chemogenetics | Tocris Bioscience
- BIBP 3226 trifluoroacetate | Tocris Bioscience 2707/1 产品信息
- Tocris Bioscience公司,Tocris Bioscience官网,Tocris ...
Biological Activity
Highly selective, high affinity MET inhibitor (Ki = 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.
Licensing Information
Sold for research purposes under agreement from Pfizer Inc.
Technical Data
| M. Wt | 468.49 |
| Formula | C19H16N8O.CH3SO3H |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 956906-93-7 |
| PubChem ID | 24852079 |
| InChI Key | HBEMHKVWZJTVOC-UHFFFAOYSA-N |
| Smiles | OCCN1N=CC(C2=CN=C3C(N(CC4=CC=C(N=CC=C5)C5=C4)N=N3)=N2)=C1.CS(=O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 46.85 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 468.49. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.13 mL | 10.67 mL | 21.35 mL |
| 5 mM | 0.43 mL | 2.13 mL | 4.27 mL |
| 10 mM | 0.21 mL | 1.07 mL | 2.13 mL |
| 50 mM | 0.04 mL | 0.21 mL | 0.43 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Eder et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res. 15 2207 PMID: 19318488
Timofeevski et al (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48 5339 PMID: 19459657
Underiner et al (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem. 10 7 PMID: 20015007
Cui et al (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6- J.Med.Chem. 55 8091 PMID: 22924734
Keywords: PF 04217903 mesylate, supplier, pfizer, PF04217903, c-met, met, mesenchymal, epithelial, transition, factor, hgfr, receptors, tyrosine, kinase, rtk, inhibitors, inhibits, anticancer, selective, MET, Receptors, MET, Receptors, Tocris Bioscience
